|
Market Closed -
Nasdaq
00:00:00 26/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.830 USD | +0.55% |
|
-3.17% | +0.55% |
Company Valuation: Alzamend Neuro, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: April | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 8.831 | - |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 103.6% | - |
| Enterprise Value (EV) | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 8.831 | 8.831 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 103.6% | 0% |
| P/E | -7.29x | -3.65x | -0.48x | -0.52x | -0.43x | -1.74x | -2.1x |
| PBR | 7.3x | - | -1.85x | - | 6.62x | 45.8x | -2.9x |
| PEG | - | -0.51x | 0x | 0x | 0x | 0x | 0.1x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -1.08x | -1.08x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.82x | -0.82x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -189 | -202.5 | -132.3 | -11.32 | -2.63 | -1.05 | -0.87 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | -7.907 | -11.26 | -8.931 | -4.121 | -7.949 | -8.2 | -8.2 |
| EBIT 1 | -12.32 | -14.87 | -9.938 | -4.497 | -8.767 | -10.8 | -10.8 |
| Net income 1 | -12.36 | -14.88 | -9.948 | -5.105 | -8.772 | -10.8 | -10.8 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 1,377.000 | 738.855 | 63.990 | 5.940 | 1.140 | 1.830 | 1.830 |
| Nbr of stocks (in thousands) | 68.9 | 71.8 | 76.3 | 734 | 3,805 | 4,826 | - |
| Announcement Date | 19/07/22 | 27/07/23 | 30/07/24 | 22/07/25 | 22/07/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.73x | - | - | - | 8.78M | |
| 33.31x | 5.98x | 17.9x | 0.97% | 48.01B | |
| 35.42x | 3.39x | 14.64x | -.--% | 45.27B | |
| 47.15x | 5.46x | 29.88x | -.--% | 40.93B | |
| -20.54x | 221.64x | -22.17x | -.--% | 42.84B | |
| 26.85x | 7.74x | 19.93x | 0.42% | 29.6B | |
| 35.29x | 5.79x | 26.32x | -.--% | 17.32B | |
| 25.91x | 2.22x | 9.63x | 1.03% | 15.34B | |
| -59.05x | 9.67x | 236.13x | -.--% | 14.84B | |
| Average | 13.62x | 32.74x | 41.53x | 0.3% | 28.24B | |
| Weighted average by Cap. | 20.38x | 41.97x | 25.55x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALZN Stock
- Valuation Alzamend Neuro, Inc.
Select your edition
All financial news and data tailored to specific country editions
